In a major clinical milestone, Prof. Lu Jian’s urology team at Beijing Haidian Hospital successfully performed a total robot-assisted radical cystectomy using the SHURUI® single-port system. The 75-year-old patient, diagnosed with recurrent muscle-invasive bladder cancer and ureteral involvement, underwent complete bladder and prostate removal with intracorporeal urinary reconstruction—all via a 3 cm umbilical incision.
Guided by a high-definition 3D camera and powered by snake-like instruments, the procedure achieved precise dissection, minimal bleeding, and zero transfusion. The entire surgical workflow was completed smoothly on the SHURUI® platform.
This case highlights the SHURUI® surgical system’s capabilities in tackling complex urologic oncology cases with minimal trauma and faster recovery. As single-port robotic technology advances, Surgerii Robotics continues to push the boundaries of ultra-minimally invasive surgery—delivering safer, more precise, and patient-centered solutions in bladder cancer treatment and beyond.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
